Comparison of Tuberculin PPD and Autoinoculation in viral warts

Efficacy of Tuberculin Purified Protein Derivative (PPD) versus Autoinoculation in multiple cutaneous warts: A comparative study - PPD- Purified Protein Derivative

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/08/020710

Enrollment

150

Registered

2019-08-14

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Tuberculin Purified Protein Derivative(PPD): To confirm existing immunity, patients will be given intradermal injection of 0.1ml of PPD antigen on volar aspect of left forearm and, pati

Eligibility

Inclusion criteria

Inclusion criteria: 1. Multiple cutaneous warts (More than 5) 2. Difficult to treat warts or recurrent warts or recalcitrant warts

Exclusion criteria

Exclusion criteria: 1. Pregnancy and lactation 2. Age less than 12 years and more than 60 years. 3. Iatrogenic or primary immunosuppression 4. Negative Immunization with BCG 5. Negative reaction to tuberculin PPD 6. Acute febrile illness 7. Generalised dermatitis 8. Patients who have received any other treatment for warts in past 3 months. 9. Ano-genital warts

Design outcomes

Primary

Measure	Time frame
Outcome of treatment will be measured in terms of clearance, recurrence, duration of treatment and adverse effects. The clinical assessment will be done by photographic measurements before, during and after treatment session. Clearance (number and size of warts): 1) Mild: 50% clearance 2) Moderate: 50-75% clearance 3) Good response: 75% clearance 4) Complete clearance: 100% clearance Timepoint: Patients of both the groups will be followed up every month till 6 months for resolution, recurrence and adverse effects.	—

Measure

Time frame

Outcome of treatment will be measured in terms of clearance, recurrence, duration of treatment and adverse effects. The clinical assessment will be done by photographic measurements before, during and after treatment session. Clearance (number and size of warts): 1) Mild: 50% clearance 2) Moderate: 50-75% clearance 3) Good response: 75% clearance 4) Complete clearance: 100% clearance Timepoint: Patients of both the groups will be followed up every month till 6 months for resolution, recurrence and adverse effects.

—

Secondary

Measure	Time frame
Recurrence and Adverse effectsTimepoint: 3months	—

Countries

India

Contacts

Public ContactChadalavada Pragathi

Kalinga Institute of Medical Sciences

kd4639@rediffmail.com9890634707

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026